We are live on ! Find out more
ONCT

Oncternal Therapeutics, Inc. Common Stock
ONCT

Delisted

ONCT was delisted on the 2nd of December, 2024.

Back to rankings

52 hedge funds and large institutions have $3.26M invested in Oncternal Therapeutics, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 11 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

4% less funds holding

Funds holding: 54 → 52 (-2)

18% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 11

29% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 7

58% less capital invested

Capital invested by funds: $7.86M → $3.26M (-$4.6M)

Holders
52
Holders Change
-2
Holders Change %
-3.7%
% of All Funds
0.82%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
9
Reduced
11
Closed
7
Calls
$4K
Puts
–
Net Calls
+$4K
Net Calls Change
-$3K

Top Buyers

Rank Fund Capital Flow
1
RB
Richmond Brothers
Michigan
+$83.3K
2
Millennium Management
Millennium Management
New York
+$49.2K
3
Renaissance Technologies
Renaissance Technologies
New York
+$10.5K
4
Morgan Stanley
Morgan Stanley
New York
+$10.4K
5
BWP
Balboa Wealth Partners
Arizona
+$9.89K

Top Sellers

Rank Fund Capital Flow
1
BC
BIT Capital
Germany
-$566K
2
BlackRock
BlackRock
New York
-$41.4K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$35.4K
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$19K
5
CWA
CM Wealth Advisors
Ohio
-$16K
Name Holding Trade Value Shares
Change 		Change in
Stake
VFA
26
Valeo Financial Advisors
Indiana
$11.9K – – –
Charles Schwab
27
Charles Schwab
California
$11.1K – – –
BWG
28
Beta Wealth Group
California
$11K – – –
AAM
29
Aureus Asset Management
Massachusetts
$10.4K – – –
TRCT
30
Tower Research Capital (TRC)
New York
$10.1K +$4.93K +748 +105%
IIA
31
IPG Investment Advisors
California
$8.17K – – –
Jane Street
32
Jane Street
New York
$7.33K +$7K +1,062 New
Mackenzie Financial
33
Mackenzie Financial
Ontario, Canada
$7.09K – – –
FPCP
34
Fort Point Capital Partners
California
$6.92K – – –
Susquehanna International Group
35
Susquehanna International Group
Pennsylvania
$6.46K -$35.4K -5,361 -85%
Bank of New York Mellon
36
Bank of New York Mellon
New York
$6.07K – – –
OIA
37
OneDigital Investment Advisors
Kansas
$4.05K -$692 -105 -15%
Osaic Holdings
38
Osaic Holdings
Arizona
$3.95K -$2.74K -415 -42%
UBS Group
39
UBS Group
Switzerland
$3.46K +$1.97K +298 +147%
Wells Fargo
40
Wells Fargo
California
$2.2K +$7 +1 +0.3%
Bank of America
41
Bank of America
North Carolina
$2.07K -$673 -102 -25%
NSIM
42
North Star Investment Management
Illinois
$1.73K – – –
BNP Paribas Financial Markets
43
BNP Paribas Financial Markets
France
$1.26K – – –
CCA
44
Column Capital Advisors
Indiana
$500 – – –
TC
45
Truvestments Capital
Florida
$152 – – –
LC
46
Lindbrook Capital
California
$104 – – –
SPIA
47
Steward Partners Investment Advisory
New York
$104 – – –
NRG
48
Nemes Rush Group
Michigan
$25 +$26 +4 New
RhumbLine Advisers
49
RhumbLine Advisers
Massachusetts
$17 +$20 +3 New
CAS
50
Coppell Advisory Solutions
Texas
$13 +$13 +2 New
1
2
3

ONCT Hedge Fund Activity: Q2 2023 in Review

52 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q2 2023, worth a combined $3.26M — down 58% from $7.86M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of ONCT and 5 opened new positions — a net loss of 2 holders — while 11 trimmed existing stakes and 9 added.

The largest buyer was Richmond Brothers, adding an estimated $83.3K. The largest seller was BIT Capital, exiting entirely with an estimated $566K sold.

  • 52 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q2 2023, down from 54 in Q1 2023.
  • Funds reported $3.26M of Oncternal Therapeutics, Inc. Common Stock stock for Q2 2023, down 58% quarter-over-quarter.
  • 5 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q2 2023 and 7 closed out, a net change of -2 holders.
  • The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q2 2023 was Richmond Brothers, an estimated $83.3K added.
  • The largest Oncternal Therapeutics, Inc. Common Stock seller in Q2 2023 was BIT Capital, an estimated $566K sold.

Based on aggregated 13F filings for Q2 2023.